Hypertension: A disease of the microcirculation?

Hypertension

Volumn 48, Issue 6, 2006, Pages 1012-1017

  Feihl, François ^a   Liaudet, Lucas ^a   Waeber, Bernard ^a   Levy, Bernard I ^b  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b HÔPITAL LARIBOISIÈRE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; CALCIUM ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIAL NITRIC OXIDE SYNTHASE; HYDRALAZINE; NIFEDIPINE; NIMODIPINE; NITRIC OXIDE; VASCULOTROPIN; VERAPAMIL;

ANGIOGENESIS; ARTERY DIAMETER; ARTERY OCCLUSION; ARTERY RESISTANCE; BLOOD PRESSURE; BLOOD VESSEL TONE; CLINICAL STUDY; DISEASE PREDISPOSITION; HYPERTENSION; MICROANGIOPATHY; MICROCIRCULATION; NONHUMAN; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SHORT SURVEY; SPONTANEOUSLY HYPERTENSIVE RAT; STEM CELL; VASCULAR RESISTANCE; VASCULAR SMOOTH MUSCLE;

ANIMALS; ANTIHYPERTENSIVE AGENTS; ARTERIOLES; HUMANS; HYPERTENSION; MICROCIRCULATION; MUSCLE CONTRACTION; MUSCLE, SMOOTH, VASCULAR; VASCULAR RESISTANCE;

EID: 33751076238     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.0000249510.20326.72     Document Type: Short Survey

References (96)

1. Wiedeman MP. Architecture. In: Renkin EM, Michel CC, Geiger SR, eds. Section 2: The Cardiovascular System. Vol. IV: Microcirculation, Part 1. Handbook of Physiology. Bethesda, MD: American Physiological Society; 1984:11-40.
2. Zweifach BW, Lipowsky HH. Pressure-flow relations in blood and lymph microcirculation. In: Renkin EM, Michel CC, Geiger SR, eds. Section 2: The Cardiovascular System. Vol. IV: Microcirculation, Part 1. Handbook of Physiology. Bethesda, MD: American Physiological Society; 1984:251-308.
3. Junqueira LC, Carneiro J. Basic Histology. 11th ed. New York, NY: McGraw-Hill; 2005:211-212.
4. Christensen KL, Mulvany MJ. Location of resistance arteries. J Vasc Res. 2001;38:1-12.
5. Davis MJ, Hill MA. Signaling mechanisms underlying the vascular myogenic response. Physiol Rev. 1999;79:387-423.
6. Levy BI, Ambrosio G, Pries AR, Struijker-Boudier HAJ. Microcirculation in hypertension-a new target for treatment? Circulation. 2001;104:735-740.
7. Uchida E, Bohr DF. Myogenic tone in isolated perfused vessels. Occurrence among vascular beds and along vascular trees. Circ Res. 1969;25:549-555.
8. Davis MJ. Myogenic response gradient in an arteriolar network. Am J Physiol. 1993;264:H2168-H2179.
9. Harder DR. Pressure-dependent membrane depolarization in cat middle cerebral artery. Circ Res. 1984;55:197-202.
10. Davis MJ, Wu X, Nurkiewicz TR, Kawasaki J, Davis GE, Hill MA, Meininger GA. Integrins and mechanotransduction of the vascular myogenic response. Am J Physiol. 2001;280:H1427-H433.
11. James MA, Tullett J, Hemsley AG, Shore AC. Effects of aging and hypertension on the microcirculation. Hypertension. 2006;47:968-974.
12. Blumenfeld JD, Laragh JH. Management of hypertensive crises: the scientific basis for treatment decisions. Am J Hypertens. 2001;14:1154-1167.
13. Neal CR, Michel CC. Effects of temperature on the wall strength and compliance of frog mesenteric microvessels. J Physiol-London. 2000;526:613-622.
14. Takase S, Lerond L, Bergan JJ, Schmid-Schonbein GW. Enhancement of reperfusion injury by elevation of microvascular pressures. Am J Physiol. 2002;282:H1387-H1394.
15. Schmid-Schonbein GW, Takase S, Bergan JJ. New advances in the understanding of the pathophysiology of chronic venous insufficiency. Angiology. 2001;52(suppl 1):S27-S34.
16. Bohlen HG. Arteriolar closure mediated by hyperresponsiveness to norepinephrine in hypertensive rats. Am J Physiol. 1979;236:H157-H164.
17. Vicaut E, Hou X. Local renin-angiotensin system in the microcirculation of spontaneously hypertensive rats. Hypertension. 1994;24:70-76.
18. Prewitt RL, Chen II, Dowell R. Development of microvascular rarefaction in the spontaneously hypertensive rat. Am J Physiol. 1982;243:H243-H251.
19. Hashimoto H, Prewitt RL, Efaw CW. Alterations in the microvasculature of one-kidney, one-clip hypertensive rats. Am J Physiol. 1987;253:H933-H940.
20. Panza JA, Garcia CE, Kilcoyne CM, Quyyumi AA, Cannon RO, 3rd. Impaired endothelium-dependent vasodilation in patients with essential hypertension. Evidence that nitric oxide abnormality is not localized to a single signal transduction pathway. Circulation. 1995;91:1732-1738.
21. Cardillo C, Campia U, Kilcoyne CM, Bryant MB, Panza JA. Improved endothelium-dependent vasodilation after blockade of endothelin receptors in patients with essential hypertension. Circulation. 2002;105:452-456.
22. Nakamura T, Prewitt RL. Effect of NG-monomethyl L-arginine on endothelium-dependent relaxation in arterioles of one-kidney, one clip hypertensive rats. Hypertension. 1991;17:875-880.
23. Lassegue B, Griendling KK. Reactive oxygen species in hypertension; an update. Am J Hypertens. 2004;17:852-860.
24. Glagov S, Vito R, Giddens DP, Zarins CK. Micro-architecture and composition of artery walls: relationship to location, diameter and the distribution of mechanical stress. J Hypertens. 1992;10(suppl):S101-S104.
25. Prewitt RL, Rice DC, Dobrian AD. Adaptation of resistance arteries to increases in pressure. Microcirculation. 2002;9:295-304.
26. Caro CG, Pedley TJ, Schroter RC, Seed WA. The Mechanics of Circulation. Oxford, United Kingdom: Oxford University Press; 1978.
27. Mulvany MJ, Baumbach GL, Aalkjaer C, Heagerty AM, Korsgaard N, Schiffrin EL, Heistad DD. Vascular remodeling. Hypertension. 1996;28:505-506.
28. Prewitt RL, Chen II, Dowell RF. Microvascular alterations in the one-kidney, one-clip renal hypertensive rat. Am J Physiol. 1984;246:H728-H732.
29. Struijker Boudier HA, le Noble JL, Messing MW, Huijberts MS, le Noble FA, van Essen H. The microcirculation and hypertension. J Hypertens. 1992;10(suppl):S147-S156.
30. Chen II, Prewitt RL, Dowell RF. Microvascular rarefaction in spontaneously hypertensive rat cremaster muscle. Am J Physiol. 1981;241:H306-H310.
31. le Noble JL, Tangelder GJ, Slaaf DW, van Essen H, Reneman RS, Struyker-Boudier HA. A functional morphometric study of the cremaster muscle microcirculation in young spontaneously hypertensive rats. J Hypertens. 1990;8:741-748.
32. Boegehold MA, Johnson MD, Overbeck HW. Pressure-independent arteriolar rarefaction in hypertension. Am J Physiol. 1991;261:H83-H87.
33. Scheidegger KJ, Wood JM, van Essen H, Struijker-Boudier HA. Effects of prolonged blockade of the renin angiotensin system on striated muscle microcirculation of spontaneously hypertensive rats. J Pharmacol Exp Ther. 1996;278:1276-1281.
34. Henrich H, Hertel R, Assmann R. Structural differences in the mesentery microcirculation between normotensive and spontaneously hypertensive rats. Pflugers Archiv. 1978;375:153-159.
35. Haack DW, Schaffer JJ, Simpson JG. Comparisons of cutaneous microvessels from spontaneously hypertensive, normotensive Wistar-Kyoto, and normal Wistar rats. Proc Soc Exp Biol Med. 1980;164:453-458.
36. Lin SZ, Sposito N, Pettersen S, Rybacki L, McKenna E, Pettigrew K, Fenstermacher J. Cerebral capillary bed structure of normotensive and chronically hypertensive rats. Microvasc Res. 1990;40:341-357.
37. Rakusan K, Cicutti N, Kazda S, Turek Z. Effect of nifedipine on coronary capillary geometry in normotensive and hypertensive rats. Hypertension. 1994;24:205-211.
38. Sabri A, Samuel JL, Marotte F, Poitevin P, Rappaport L, Levy BI. Microvasculature in angiotensin II-dependent cardiac hypertrophy in the rat. Hypertension. 1998;32:371-375.
39. Kobayashi N, Kobayashi K, Hara K, Higashi T, Yanaka H, Yagi S, Matsuoka H. Benidipine stimulates nitric oxide synthase and improves coronary circulation in hypertensive rats. Am J Hypertens. 1999;12:483-491.
40. Rakusan K, Cicutti N, Maurin A, Guez D, Schiavi P. The effect of treatment with low dose ACE inhibitor and/or diuretic on coronary microvasculature in stroke-prone spontaneously hypertensive rats. Microvasc Res. 2000;59:243-254.
41. Levy BI, Duriez M, Samuel JL. Coronary microvasculature alteration in hypertensive rats. Effect of treatment with a diuretic and an ACE inhibitor. Am J Hypertens. 2001;14:7-13.
42. Pu Q, Larouche I, Schiffrin EL. Effect of dual angiotensin converting enzyme/neutral endopeptidase inhibition, angiotensin converting enzyme inhibition, or AT1 antagonism on coronary microvasculature in spontaneously hypertensive rats. Am J Hypertens. 2003;16:931-937.
43. Tomanek RJ, Searls JC, Lachenbruch PA. Quantitative changes in the capillary bed during developing, peak, and stabilized cardiac hypertrophy in the spontaneously hypertensive rat. Circ Res. 1982;51:295-304.
44. Rakusan K, Flanagan MF, Geva T, Southern J, Van Praagh R. Morphometry of human coronary capillaries during normal growth and the effect of age in left ventricular pressure-overload hypertrophy. Circulation. 1992;86:38-46.
45. Ruedemann AD. Conjunctival vessels. J Am Med Ass. 1933;101:1477-1481.
46. Sullivan JM, Prewitt RL, Josephs JA. Attenuation of the microcirculation in young patients with high-output borderline hypertension. Hypertension. 1983;5:844-851.
47. Serne EH, Gans ROB, ter Maaten JC, Tangelder GJ, Donker AJM, Stehouwer CDA. Impaired skin capillary recruitment in essential hypertension is caused by both functional and structural capillary rarefaction. Hypertension. 2001;38:238-242.
48. Antonios TFT, Singer DRJ, Markandu ND, Mortimer PS, MacGregor GA. Structural skin capillary rarefaction in essential hypertension. Hypertension. 1999;33:998-1001.
49. Prasad A, Dunnill GS, Mortimer PS, MacGregor GA. Capillary rarefaction in the forearm skin in essential hypertension. J Hypertens. 1995;13:265-268.
50. Antonios TFT, Singer DRJ, Markandu ND, Mortimer PS, MacGregor GA. Rarefaction of skin capillaries in borderline essential hypertension suggests an early structural abnormality. Hypertension. 1999;34:655-658.
51. Antonios TFT, Rattray FM, Singer DRJ, Markandu ND, Mortimer PS, MacGregor GA. Rarefaction of skin capillaries in normotensive offspring of individuals with essential hypertension. Heart. 2003;89:175-178.
52. Noon JP, Walker BR, Webb DJ, Shore AC, Holton DW, Edwards HV, Watt GC. Impaired microvascular dilatation and capillary rarefaction in young adults with a predisposition to high blood pressure. J Clin Invest. 1997;99:1873-1879.
53. Debbabi H, Uzan L, Mourad JJ, Safar M, Levy BI, Tibirica E. Increased skin capillary density in treated essential hypertensive patients. Am J Hypertens. 2006;19:477-483.
54. Struyker-Boudier HA, le Noble JL, Slaaf DW, Smits JF, Tangelder GJ. Microcirculatory changes in cremaster muscle during early spontaneous hypertension in the rat. J Hypertens. 1988;6(suppl):S185-S187.
55. Meirelles Pereira LM, Mandarim-de-Lacerda CA. Effect of antihypertensive drugs on the myocardial microvessels in rats with nitric oxide blockade. Pathol Res Pract. 2000;196:305-311.
56. Kubis N, Besnard S, Silvestre JS, Feletou M, Huang PL, Levy BI, Tedgui A. Decreased arteriolar density in endothelial nitric oxide synthase knockout mice is due to hypertension, not to the constitutive defect in endothelial nitric oxide synthase enzyme. J Hypertens. 2002;20:273-280.
57. Kobayashi N, DeLano FA, Schmid-Schönbein GW. Oxidative stress promotes endothelial cell apoptosis and loss of microvessels in the spontaneously hypertensive rats. Arterioscler Thromb Vasc Biol. 2005;25:2114-2121.
58. le Noble FA, Stassen FR, Hacking WJ, Struijker Boudier HA. Angiogenesis and hypertension. J Hypertens. 1998;16:1563-1572.
59. Kiefer FN, Neysari S, Humar R, Li W, Munk VC, Battegay EJ. Hypertension and angiogenesis. Curr Pharm Design. 2003;9:1733-1744.
60. Sane DC, Anton L, Brosnihan KB. Angiogenic growth factors and hypertension. Angiogenesis. 2004;7:193-201.
61. Loomans CJ, Dao HH, van Zonneveld AJ, Rabelink TJ. Is endothelial progenitor cell dysfunction involved in altered angiogenic processes in patients with hypertension? Curr Hypertens Rep. 2004;6:51-54.
62. Lee PC, Salyapongse AN, Bragdon GA, Shears LL, 2nd, Watkins SC, Edington HD, Billiar TR. Impaired wound healing and angiogenesis in eNOS-deficient mice. Am J Physiol. 1999;277:H1600-H1608.
63. Dulak J, Jozkowicz A, Dembinska-Kiec A, Guevara I, Zdzienicka A, Zmudzinska-Grochot D, Florek I, Wojtowicz A, Szuba A, Cooke JP. Nitric oxide induces the synthesis of vascular endothelial growth factor by rat vascular smooth muscle cells. Arterioscler Thromb Vasc Biol. 2000;20:659-666.
64. Kiefer FN, Misteli H, Kalak N, Tschudin K, Fingerle J, Van der Kooij M, Stumm M, Sumanovski LT, Sieber CC, Battegay EJ. Inhibition of NO biosynthesis, but not elevated blood pressure, reduces angiogenesis in rat models of secondary hypertension. Blood Press. 2002;11:116-124.
65. Ichiki T. Role of renin angiotensin system in angiogenesis: it is still elusive. Arterioscler Thromb Vasc Biol. 2004;24:622-624.
66. Felmeden DC, Spencer CG, Belgore FM, Blann AD, Beevers DG, Lip GY. Endothelial damage and angiogenesis in hypertensive patients: relationship to cardiovascular risk factors and risk factor management. Am J Hypertens. 2003;16:11-20.
67. Nadar SK, Blann A, Beevers DG, Lip GY. Abnormal angiopoietins 1&2, angiopoietin receptor Tie-2 and vascular endothelial growth factor levels in hypertension: relationship to target organ damage [a sub-study of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT)]. J Intern Med. 2005;258:336-343.
68. Asahara T, Murohara T, Sullivan A, Silver M, van der Zee R, Li T, Witzenbichler B, Schatteman G, Isner JM. Isolation of putative progenitor endothelial cells for angiogenesis. Science. 1997;275:964-967.
69. Carmeliet P. Angiogenesis in health and disease. Nat Med. 2003;9:653-660.
70. Hill JM, Zalos G, Halcox JP, Schenke WH, Waclawiw MA, Quyyumi AA, Finkel T. Circulating endothelial progenitor cells, vascular function, and cardiovascular risk [see comment]. N Engl J Med. 2003;348:593-600.
71. Imanishi T, Moriwaki C, Hano T, Nishio I. Endothelial progenitor cell senescence is accelerated in both experimental hypertensive rats and patients with essential hypertension. J Hypertens. 2005;23:1831-1837.
72. Bahlmann FH, de Groot K, Mueller O, Hertel B, Haller H, Fliser D. Stimulation of endothelial progenitor cells: a new putative therapeutic effect of angiotensin II receptor antagonists. Hypertension. 2005;45:526-529.
73. Werner N, Kosiol S, Schiegl T, Ahlers P, Walenta K, Link A, Bohm M, Nickenig G. Circulating endothelial progenitor cells and cardiovascular outcomes. N Engl J Med. 2005;353:999-1007.
74. DeLano FA, Schmid-Schonbein GW, Skalak TC, Zweifach BW. Penetration of the systemic blood pressure into the microvasculature of rat skeletal muscle. Microvasc Res. 1991;41:92-110.
75. Greene AS, Tonellato PJ, Lui J, Lombard JH, Cowley AWJ. Microvascular rarefaction and tissue vascular resistance in hypertension. Am J Physiol. 1989;256:H126-H131.
76. Greene AS, Tonellato PJ, Zhang Z, Lombard JH, Cowley AW Jr. Effect of microvascular rarefaction on tissue oxygen delivery in hypertension. Am J Physiol. 1992;262:H1486-H1493.
77. Lombard JH, Frisbee JC, Greene AS, Hudetz AG, Roman RJ, Tonellato PJ. Microvascular flow and tissue PO2 in skeletal muscle of chronic reduced renal mass hypertensive rats. Am J Physiol. 2000;279:H2295-H2302.
78. Boegehold MA, Bohlen HG. Arteriolar diameter and tissue oxygen tension during muscle contraction in hypertensive rats. Hypertension. 1988;12:184-191.
79. Engelson ET, Schmid-Schonbein GW, Zweifach BW. The microvasculature in skeletal muscle. II. Arteriolar network anatomy in normotensive and spontaneously hypertensive rats. Microvasc Res. 1986;31:356-374.
80. Dusseau J, Hutchins PM. Calcium entry blockers stimulate vasoproliferation on the chick chorioallantoic membrane. Int J Microcirc Clin Exp. 1993;13:219-231.
81. Volpert OV, Ward WF, Lingen MW, Chesler L, Solt DB, Johnson MD, Molteni A, Polverini PJ, Bouck NP. Captopril inhibits angiogenesis and slows the growth of experimental tumors in rats. J Clin Invest. 1996;98:671-679.
82. Fabre JE, Rivard A, Magner M, Silver M, Isner JM. Tissue inhibition of angiotensin-converting enzyme activity stimulates angiogenesis in vivo. Circulation. 1999;99:3043-3049.
83. Silvestre JS, Bergaya S, Tamarat R, Duriez M, Boulanger CM, Levy BI. Proangiogenic effect of angiotensin-converting enzyme inhibition is mediated by the bradykinin B(2) receptor pathway. Circ Res. 2001;89:678-683.
84. Unger T, Mattfeldt T, Lamberty V, Bock P, Mall G, Linz W, Scholkens BA, Gohlke P. Effect of early onset angiotensin converting enzyme inhibition on myocardial capillaries. Hypertension. 1992;20:478-482.
85. Bock P. The arterial length-densities under preventive angiotensin-converting-enzyme inhibiting treatment in the myocardium of spontaneously hypertensive rats. Basic Res Cardiol. 1998;93:18-22.
86. Gohlke P, Kuwer I, Schnell A, Amann K, Mall G, Unger T. Blockade of bradykinin B2 receptors prevents the increase in capillary density induced by chronic angiotensin-converting enzyme inhibitor treatment in stroke-prone spontaneously hypertensive rats. Hypertension. 1997;29:478-482.
87. Emanueli C, Salis MB, Stacca T, Pinna A, Gaspa L, Madeddu P. Angiotensin AT(1) receptor signalling modulates reparative angiogenesis induced by limb ischaemia. Br J Pharmacol. 2002;135:87-92.
88. Munzenmaier DH, Greene AS. Opposing actions of angiotensin II on microvascular growth and arterial blood pressure. Hypertension. 1996;27:760-765.
89. Sasaki K, Murohara T, Ikeda H, Sugaya T, Shimada T, Shintani S, Imaizumi T. Evidence for the importance of angiotensin II type 1 receptor in ischemia-induced angiogenesis. J Clin Invest. 2002;109:603-611.
90. Walther T, Menrad A, Orzechowski HD, Siemeister G, Paul M, Schirner M. Differential regulation of in vivo angiogenesis by angiotensin II receptors. FASEB J. 2003;17:2061-2067.
91. de Boer RA, Pinto YM, Suurmeijer AJ, Pokharel S, Scholtens E, Humler M, Saavedra JM, Boomsma F, van Gilst WH, van Veldhuisen DJ. Increased expression of cardiac angiotensin II type 1 (AT(1)) receptors decreases myocardial microvessel density after experimental myocardial infarction. Cardiovasc Res. 2003;57:434-442.
92. Forder JP, Munzenmaier DH, Greene AS. Angiogenic protection from focal ischemia with angiotensin II type 1 receptor blockade in the rat. Am J Physiol. 2005;288:H1989-H1996.
93. Silvestre JS, Tamarat R, Senbonmatsu T, Icchiki T, Ebrahimian T, Iglarz M, Besnard S, Duriez M, Inagami T, Levy BI. Antiangiogenic effect of angiotensin II type 2 receptor in ischemia-induced angiogenesis in mice hindlimb. Circ Res. 2002;90:1072-1079.
94. Benndorf R, Boger RH, Ergun S, Steenpass A, Wieland T. Angiotensin II type 2 receptor inhibits vascular endothelial growth factor-induced migration and in vitro tube formation of human endothelial cells. Circ Res. 2003;93:438-447.
95. AbdAlla S, Lother H, Abdel-tawab AM, Quitterer U. The angiotensin II AT2 receptor is an AT1 receptor antagonist. J Biol Chem. 2001;276:39721-39726.
96. Tsutsumi Y, Matsubara H, Masaki H, Kurihara H, Murasawa S, Takai S, Miyazaki M, Nozawa Y, Ozono R, Nakagawa K, Miwa T, Kawada N, Mori Y, Shibasaki Y, Tanaka Y, Fujiyama S, Koyama Y, Fujiyama A, Takahashi H, Iwasaka T. Angiotensin II type 2 receptor overexpression activates the vascular kinin system and causes vasodilation. J Clin Invest. 1999;104:925-935.